Immunovant is transitioning from a pure development-stage biotech to early commercialization, evidenced by its first $7.1M revenue in 2027Q1 with a 100% gross margin. However, the company's aggressive R&D investment, which nearly doubled from $66.1M in 2024Q4 ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue emerged at $7.1M in 2027Q1 with a 100% gross margin, but R&D expenses surged to $142.6M, driving operating losses to -$153.2M and a net margin of -21.6%.
IMVT-1402 demonstrated strong open-label activity in difficult-to-treat rheumatoid arthritis with no new safety signals, supporting its potential efficacy.
D2T RA and CLE updates expected in 2H 2026 serve as near-term catalysts for potential stock re-rating.
With over $900 million in cash, Immunovant is well-funded to advance its clinical programs through announced indications.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.75-19.3% vs -$0.63 | $7M+0.0% vs $7M |
Q2 2026 May 20, 2026 | -$0.73-23.3% vs -$0.59 | — vs — |
Q1 2026 Feb 6, 2026 | -$0.61+15.3% vs -$0.72 | — vs $6M |
Q4 2025 Nov 10, 2025 | -$0.73-1.4% vs -$0.72 | — vs — |
Algert Global LLC increased its stake in Immunovant, Inc. (NASDAQ: IMVT) by 51.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 159,840 shares of the company's stock after buying an additional 54,070 shares during the quarter. Algert Global LLC owned about
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $43.89 and last traded at $43.71, with a volume of 1216514 shares. The stock had previously closed at $41.82. Wall Street Analysts Forecast Growth A number of analysts recently
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Benchmark IMVT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Immunovant, Inc. (IMVT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $34.54 | $7.13B | -12.47 | — | — | -64.82% | — | |
| $3.48 | $859.66M | -13.38 | 22.09% | -12.35% | -36% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $41.65 | $4.86B | -13.06 | — | — | -94.56% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Immunovant, Inc. (IMVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Immunovant, Inc. (IMVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 20, 2026·SEC
Feb 6, 2026·SEC
Get notified when IMVT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Immunovant, Inc. (IMVT) stock FAQ — growth, dividends, profitability & financials explained
Immunovant, Inc. (IMVT) reported $7.1M in revenue for fiscal year 2026.
Immunovant, Inc. (IMVT) reported a net loss of $538.2M for fiscal year 2026.
Immunovant, Inc. (IMVT) has a return on equity (ROE) of -64.8%. Negative ROE indicates the company is unprofitable.
Immunovant, Inc. (IMVT) had negative free cash flow of $414.3M in fiscal year 2026, likely due to heavy capital investments.
